Antacid Therapy May Lead to Lung Infections in Esbriet-Treated IPF Patients, Study Reports

Boehringer Ingelheim Enrolls First PF-ILD Patient in Phase 3 Trial of Ofev Therapy

Boehringer Ingelheim has enrolled its first patient with progressive fibrosing interstitial lung disease (PF-ILD) in a Phase 3 clinical trial investigating the effectiveness and safety of treatment with Ofev (nintedanib). Patients with ILDs, also called diffuse parenchymal lung diseases, are often unable to breathe. The problem stems from impaired gas exchange — a consequence…

What You Need to Know About Esbriet

Esbriet (pirfenidone), is an anti-fibrotic drug used in the treatment of patients with mild to moderate idiopathic pulmonary fibrosis (IPF). It’s made by the pharmaceutical company, Genentech. Find out more about Esbriet for treating idiopathic pulmonary fibrosis. A study by researchers at the University of Wisconsin found that…

American Lung Association Initiative for Healthy Air

Healthy Air is an initiative run by the American Lung Association (ALA) that aims to education people on how to improve the air they breathe, avoid pollution and help influence public policy to improve the air quality. MORE: Four ways the American Lung Association helps patients manage their lung disease.

Holding Tight to What’s Positive Up Ahead

Throughout this yearlong journey with idiopathic pulmonary fibrosis (IPF), to which I am an unwilling participant, I have often spoken with others about the benefits of having something positive to look forward to. Knowing something good is on the horizon helps in coping with this disease — whether…